Background: Antimicrobial resistance to ciprofloxacin is rising worldwide, especially in bacteria causing urinary tract infections (UTIs). Prudent use of current antibiotic drugs is therefore necessary.
Introduction
Urinary tract infections (UTIs) are common in women, especially after menopause. Nearly 50% of all women experience at least one UTI during their lifetime. 1 Fluoroquinolones are often prescribed for complicated UTIs, such as pyelonephritis. 2 However, ciprofloxacin, for example, is also widely used in uncomplicated UTIs. 3 With the increasing use of fluoroquinolones, selection of ciprofloxacin-resistant uropathogens has become widespread worldwide, ranging from 2% to 69% for uncomplicated and up to 98% for complicated UTIs. 4 In Europe, resistance to ciprofloxacin in uncomplicated UTIs varied from 4.8% in France, 20 .3% in Germany, 30 .8% in Spain, 7.3% in Sweden to 15 .3% in the UK in 2014, 5 while in the USA 17.1% resistance to ciprofloxacin was seen in an outpatient population with UTIs. 6 Although antimicrobial resistance (AMR) is low in the Netherlands, resistance of Escherichia coli to ciprofloxacin in outpatients was 10% in 2014, 7 while it was 12% in a study with a mixed population of both inpatients and outpatients with complicated UTIs in 2004-09. 8 The WHO has proclaimed AMR to be one of the greatest current threats to global health. Furthermore, AMR is directly associated with the use of antibiotics. 9 Unfortunately, there are very few new antibiotic drugs in the pipeline, 10 and prudent use of current antibiotic drugs has been advocated in order to decrease AMR rates. 11 This also involves dose adjustment to obtain proper drug levels, since low levels of ciprofloxacin will influence the mutant selection window, resulting in faster selection of resistant subpopulations. 12 Age and renal insufficiency influence the concentrations of ciprofloxacin in blood and urine, 13, 14 and furthermore concomitantly prescribed drugs may change the pharmacokinetics of ciprofloxacin, such as bioavailability or excretion. Taking age and renal function into account or adjusting for co-medication may result in improved drug levels and less selection of ciprofloxacinresistant bacteria. However, other modifiable factors may also play a role. Therefore, we studied risk factors for ciprofloxacinresistant E. coli in a primary care population with UTI and identified modifiable factors that were associated with ciprofloxacin resistance.
Patients and methods

Source population
This nested case-control analysis was embedded in the Rotterdam Study, which was designed as a prospective population-based cohort study of chronic diseases as a response to demographic changes that lead to an increase of elderly people in most populations. The aim of the study is to investigate determinants of disease occurrence and progression in the elderly and to investigate potentially modifiable determinants in order to be able to develop preventive strategies. In 1990 all inhabitants aged 55 years and older living in the well-defined Ommoord district in Rotterdam, the Netherlands were invited to participate (response rate 78%). In an extension in 2000 and 2006, two further cohorts were included with inhabitants aged 55 years and older, and 45 years and older, respectively, resulting in a total of 14 926 participants. All participants are invited every 3 -4 years for follow-up interviews and examinations. The majority of people included in the study cohort are of Dutch ancestry and are representative of the Dutch population at that age.
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Ethics
The Rotterdam Study has been approved by the Medical Ethics Committee of the Erasmus MC and by the Ministry of Health, Welfare and Sport of the Netherlands, on the basis of the Wet Bevolkingsonderzoek ERGO (Population Studies Act: Rotterdam Study). All participants provided written informed consent for their participation in the study and for researchers to obtain information from their treating physicians.
Cases and controls
In the Rotterdam area all laboratory services for community-dwelling patients of general practitioners are provided by Star Medisch Diagnostisch Centrum (Star-MDC). The study population consisted of participants from the Rotterdam Study with at least one urinary culture positive for E. coli between 1 January 2000 and 31 January 2014. Cultures and uricult slides were collected from midstream urine. A standardized volume of urine was cultured on agar plates and incubated overnight at 358C; the same was done for colonies of microorganisms from uricult slides. A culture was considered positive when at least 10 3 cfu/mL were present. Susceptibility to ciprofloxacin was until 2010 determined by disc diffusion, and afterwards with the VITEK 2 system (VITEK AMS; bioMé rieux Vitek Systems, Inc., Hazelwood, MO, USA). Until 2013 the CSLI criteria 15 were used for zone size and MIC interpretations of ciprofloxacin. After 2013 the EUCAST criteria 16 were applied. In our study intermediate results for ciprofloxacin were categorized as resistant. All isolates after 2013 that were resistant to ciprofloxacin had an MIC .4 mg/L. Only the first culture positive for E. coli of each patient, and thus one culture per patient in total, was used for the analysis. Cases were defined as participants with a positive urine culture with ciprofloxacin-resistant E. coli; controls were participants with a positive urine culture with ciprofloxacin-susceptible E. coli. 
Medication use
Medication use of participants in the Rotterdam Study has been monitored since 1 January 1991, through computerized records from pharmacies in the Ommoord district. The data include the Anatomical Therapeutical Chemical code, dispensing date, total number of drug units per prescription, the prescribed daily number of units and the product names of drugs. The number of prescriptions of fluoroquinolones before first urinary culture since the beginning of pharmacy data collection was determined. It was separated into prescriptions before the start of the study period (historical use) and during this period. Both variables were categorized in none, one, two and three or more prescriptions. Prescriptions in the month before culture were not included, since it was assumed that the culture was sent in because of persisting symptoms despite fluoroquinolone use. The same information was collected for the antibiotic groups J01C (b-lactam antibacterials, penicillins), J01EA (trimethoprim and derivatives) and J01XE (nitrofuran derivatives), which was dichotomized into use or no use. Furthermore, the timing of the last fluoroquinolone prescription, defined as the time between last fluoroquinolone prescription and culture, was calculated and categorized into: no prescription; .12 months ago; 3 -12 months ago; 1 -3 months ago. Again, participants with a prescription in the month before culture were excluded from this variable. Concomitant drug use was defined as drug use during the 90 day period before filling the most recent prescription of any fluoroquinolone before culture. Investigated drugs were antacids (A02A); H 2 -receptor antagonists (A02BA); proton pump inhibitors (A02BC); vitamins (A11); mineral supplements (A12); diuretics (C03); calcium channel blockers (C08); drugs acting on the renin -angiotensin system (C09) and corticosteroids for systemic use (H02). The main fluoroquinolones prescribed were ciprofloxacin (43%), norfloxacin (38%) and ofloxacin (15%).
Diet
By using an extensive semi-quantitative food frequency questionnaire (FFQ), the habitual food intake of participants of several cohorts of the Rotterdam Study was determined . The questionnaire consisted of 389 food items and questions about dietary habits. This FFQ has been developed on the basis of an existing validated FFQ developed for Dutch adults. 17, 18 Participants were asked to give for each food item the frequency of consumption (in times per month or per week), the number of servings per day (expressed in standardized household measures) as well as the preparation method. All food items were calculated to grams per day. Total energy intake was calculated using the Dutch Food Composition Table of 2006 and 2011 . Participants who reported an extreme energy intake of ,500 kcal/day or .5000 kcal/day were excluded a priori from analysis; 18 participants (3.4%) fell into this category.
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To account for potential measurement error and confounding, dietary intake was adjusted for total energy intake, using the residual method. Briefly, a linear regression of every dietary variable was performed with total energy intake per day in calories as an outcome. Residuals were added to the coefficients of the formula times the median food intake per day of the population [residuals +(b0 +b1) × median calorie intake per day], resulting in dietary intake fixed to the median energy intake of the population, as explained by Willett et al. 19 The energy-adjusted dietary variables were categorized in tertiles.
Analysis and statistical methods
Multivariate binary logistic regression was performed with as an outcome variable the presence or absence of ciprofloxacin-resistant E. coli to determine the OR and 95% CI of several determinants. Variables for the multivariate models were considered on the basis of clinical grounds and based on the literature: 20 -25 the number of prescriptions of fluoroquinolones before first culture during the study period, historical use of fluoroquinolones, timing of the last fluoroquinolone prescription, sex, age, kidney function, diabetes, BMI, SES, and a variable consisting of the period between the start date of the study and the date of culture (follow-up time). The number of prescriptions of fluoroquinolones (model 1) and the timing of the last fluoroquinolone prescription (model 2) were studied in separate models because of their intrinsic similarity. Variables were selected on the basis of clinical relevance, while backward selection (P, 0.2) was used to determine the final model. Because of clinical relevance, BMI, SES and Dutch Healthy Diet index (DHDI) were kept fixed in the models, while historical use of fluoroquinolones was not. These variables were separately studied in an extra analysis by removing them one by one from the model to see whether these would change the OR by .10%. Furthermore, use of other antibiotics and of concomitantly described drugs possibly affecting the pharmacokinetics of fluoroquinolones were also analysed in model 1.
Dietary meat intake was analysed in multivariate model 1, which included an additional score, the DHDI of each participant, which reflects the overall healthy diet pattern assessed by adherence to the Dutch Guidelines for a Healthy Diet, which was adapted from van Lee et al. 26 and included the following components: intake of fibre, vegetables, fruit, fish, saturated fatty-acids, mono-trans fatty-acids, sodium and alcohol. For each meat (beef, chicken, pork and offal) the effect of substituting one of the others was estimated by including simultaneously these meat types as continuous variables in the model. This was performed in order to exclude the possibility that the associations found were not true associations, but caused by a high correlation with the intake of another meat. The risk difference for the substitution effect was derived from the difference between the regression coefficients when the food items were added alone and simultaneously, where a small difference would indicate that this effect can be neglected. 27 To account for potential bias associated with missing data, missing values on kidney function (2.0%), BMI (4.6%) and SES (1.4%) were imputed using multiple imputation (n¼10 imputations). 28 Details of the procedure are described in Table S1 (available as Supplementary data at JAC Online), while Table S2 shows the characteristics of the study population before and after the procedure.
A P value ,0.05 was considered as statistically significant. Statistical analyses were performed with IBM SPSS Statistics 21.
Results
The source population consists of 14 926 participants of the Rotterdam Study. From this population, 1999 urinary cultures positive for E. coli were collected from 1080 individuals. These individuals comprise the current study population. General characteristics are shown in Table 1 . The study population consisted of more women (80.3%) compared with the total population of the Rotterdam Study (59.1%). Ciprofloxacin-resistant E. coli was found in 10.2% of all urine cultures positive for E. coli. The percentage of resistant cultures did not change over the study period. In the 415 individuals with one or more prescriptions of fluoroquinolones before the first urinary culture, ciprofloxacin resistance was higher (18.3%). Thirty-four (30.9%) patients with a UTI caused by ciprofloxacin-resistant E. coli had no prescriptions of fluoroquinolones during the study period before culture compared with 631 (65.1%) of patients with a UTI caused by ciprofloxacinsusceptible E. coli. In the subgroup of participants with at least one prescription of a fluoroquinolone before culture, the median defined daily dose was 1.0 and the median duration was 7.0 days. Neither of these was significantly associated with ciprofloxacin resistance (data not shown). Dietary intake of several types of meat (beef, chicken, offal and pork) and having a urinary culture with a ciprofloxacin-resistant E. coli was investigated in a subgroup of 507 individuals for which data on nutritional intake had been collected. In model 1, high intake of pork (highest tertile versus lowest tertile: OR 3.68; 95% CI 1.36 -9.99; trend: OR 1.97; 95% CI 1.19 -3.25) and a high intake of chicken (highest versus lowest tertile: OR 2.72; 95% CI 1.08-6.85; trend: OR 1.67; 95% CI 1.05-2.65) were associated with ciprofloxacin resistance after adjustment for confounders (Table 3) . Substituting beef with pork showed some effect on the association with ciprofloxacin resistance; however, this effect was not significant (data not shown). No effects were seen for the other kinds of meat.
The concomitant prescription of other drugs during ciprofloxacin prescription is shown in Table 4 . After adjustment for age, sex, kidney function, diabetes, BMI, SES and follow-up time a significant association could be demonstrated for mineral supplements (OR 2.51; 95% CI 1.20 -5.22), which mainly consisted of calcium supplements, and for proton pump inhibitors (OR 2.04; 95% CI 1.18-3.51).
Discussion
In this study, we investigated the association of modifiable determinants and the selection of ciprofloxacin-resistant E. coli causing UTI in an elderly community-based cohort. Risk factors such as prior fluoroquinolone use and higher age were present, whereas other reported risk factors such as diabetes were not significant Risk factors for resistance to ciprofloxacin in UTIs JAC in our study. Furthermore, a high intake of pork and chicken as well as the concomitant prescription of calcium supplements or proton pump inhibitors with fluoroquinolones were associated with the selection of ciprofloxacin-resistant E. coli.
In this community-dwelling cohort of mainly elderly women, concomitant prescription of fluoroquinolones and calcium supplements is likely since both recurrent UTIs and the use of calcium supplements are common in postmenopausal women, as described previously in an inpatient population. 29 Calcium, as well as compounds containing magnesium and aluminium, belong to the group of di-or trivalent cation-containing compounds (DTCCs), which have been shown to have effects on the bioavailability of fluoroquinolones. 30 They are known to change the pharmacokinetics of several fluoroquinolones by diminishing their solubility and thereby decreasing absorption, resulting in an increase in excretion through the intestines, lower blood levels and lower urine levels. 31 -33 Proton pump inhibitors, such as omeprazole, have also been found to diminish the bioavailability of fluoroquinolones, probably by increasing gastric pH, 34, 35 although this could not be confirmed in another study. 36 Pharmacokinetic studies have suggested a higher risk of resistance when blood levels of ciprofloxacin are low. 37 Indeed, concomitant use of Mulder et al.
levofloxacin and DTCCs has been shown to increase selection of fluoroquinolone-resistant bacteria. 38 Here, we showed that concomitant prescription of calcium supplements and proton pump inhibitors with fluoroquinolones was associated with ciprofloxacinresistant E. coli.
High intake of pork and high intake of chicken may also be potential risk factors. For chicken, it is known that a substantial amount of E. coli isolates are present in samples of raw meat in the Netherlands. This is in contrast to pork, where these percentages are low. 7 In addition, substitution of other meats could not explain the association between high pork intake and ciprofloxacin resistance. An association between antibiotic use in animals and the resistance rate of Gram-negative organisms isolated in humans was first described in the 1960s, 39 followed by a number of other reports. 40 -42 Furthermore, a recent population-based study on the gut microbiota showed a correlation between meat consumption and overall microbiome community variation. 43 Evidence supporting transmission of microorganisms from retail meat to humans has been reported for extended-spectrum b-lactamase-producing E. coli. 44 Although AMR was higher in meat source Klebsiella pneumoniae than in phylogenetically closely related clinical isolates, 41 this does not exclude the possibility of transmission, since transmission of plasmids carrying colistin resistance genes from E. coli to K. pneumoniae has been made likely. 45 It was shown that the introduction of fluoroquinolones into broiler chicken production in the USA was associated with an increase in ciprofloxacin-resistant camplylobacters in humans. 46 On the other hand, in Australia and Finland, where the use of fluoroquinolones in food animals is prohibited, only a low prevalence of fluoroquinolone resistance has been found in human samples: in 2010 in E. coli only 5.2% and far below 10%, respectively. 47, 48 Also, in 99 women with UTIs, an association was shown between more frequent consumption of chicken and MDR E. coli in UTIs, and associations have also been found between more frequent consumption of pork and ampicillin-or cephalosporin-resistant E. coli in UTIs. 49 To our knowledge, this study is the first to report an association between meat intake and ciprofloxacin-resistant E. coli in UTIs.
Previously established risk factors for the development of fluoroquinolone resistance were age and use of fluoroquinolones. 20, 24, 25 The literature contains conflicting results for kidney function, possibly caused by differences in adjustment for confounding. 21, 22 We also showed different results in the different models. The dose of fluoroquinolones is adapted in patients with renal insufficiency, which is a possible explanation, although 2 ). In model 1 are included: age, sex, BMI, kidney function, diabetes, SES, follow-up time and number of fluoroquinolone prescriptions. In model 2 are included: age, sex, BMI, kidney function, diabetes, SES, follow-up time and the timing of last fluoroquinolone prescription. Seventy-three (6.8%) particpants were excluded in model 2 because they had a presciption of a fluoroquinolone in the first month before culture. In model 1 the prescriptions in the first month before culture were not included in the total number. a Significant with P,0.05. OR and 95% CI for resistance to ciprofloxacin in UTIs for drugs prescribed concomittantly with the last fluoroquinolone prescription before culture, both unadjusted and adjusted. ORs were adjusted for age, sex, kidney function, diabetes, BMI, SES and follow-up time. Proton pump inhibitors were thought to possibly change the pharmacokinetics of fluoroquinolones, while H 2 -receptor antagonists were analysed as another major group of acid-lowering drugs. Mineral supplements and vitamins were analysed for their potential interaction with fluoroquinolones in the gastrointestinal tract. Diuretics and agents acting on the renin-angiotensin system were selected because of their potential influence on the secretion of fluoroquinolones by the kidney, while calcium channel blockers are the other large group of antihypertensive drugs. Corticoids were studied because of their effect on the immune system. a Significant with P,0.05.
Risk factors for resistance to ciprofloxacin in UTIs
JAC
dose itself was not associated with ciprofloxacin resistance in the group of participants with at least one fluoroquinolone prescription (data not shown). Furthermore, renal insufficiency has been reported as a risk factor for UTIs, while UTIs could progress kidney disease. 50 -52 We therefore cannot conclude whether renal insufficiency should be considered as a risk factor for ciprofloxacin resistance. Although we did not confirm an association with diabetes, others have done so. 23 Patients with diabetes have more UTIs and use more antibiotics. We corrected for fluoroquinolone use, possibly explaining this difference. Furthermore, in model 2, sex is borderline significant, while it is not in model 1, probably caused by the fact that men were prescribed more fluoroquinolones than women, for which is not corrected in model 2. Finally, some studies showed associations between the previous use of other antimicrobial drugs, such as nitrofurantoin. 53, 54 We studied the previous use of penicillins, trimethoprim derivatives and nitrofuran derivatives, but found no significant associations.
Our study has strengths, but also some potential limitations. The size of the cohort, its real-life population-based character, the length of follow-up, and the prospective and unbiased collecting of information on determinants and outcome are substantial strengths of this study. A limitation may be that dietary data were collected using self-report, which is prone to measurement error. To account for potential systematic error, we adjusted the dietary variables for energy intake. 19 Moreover, the FFQ has been validated in a comparable population and showed adequate ranking of individuals according to their dietary intake. 17, 18 Furthermore, we cannot take into account calcium supplements obtained over the counter without prescription and we cannot exclude that individuals who were concomitantly prescribed calcium supplements or proton pump inhibitors and ciprofloxacin were warned not to use both drugs at the same time. However, both would have led to an underestimation of the association. We also cannot exclude the possibility that the urinary tract of some patients was only colonized by E. coli. We choose to keep the term UTI, since the urine was sent in by general practioners, which, in the Netherlands, is only done when a UTI is suspected and under strict restrictions. 55 A final limitation is the number of statistical tests carried out in this study. However, most of our analyses were hypothesis driven. For those that were not, we preferred to study them one-by-one to see if they made sense and if so, to report them with the advice to replicate instead of using a Bonferroni correction. The risk with Bonferroni correction may be that interesting new genuine associations are missed. Given the multiple comparisons, interpretation of the results should be made with caution.
In conclusion, in an elderly primary care cohort possible modifiable factors for the selection of ciprofloxacin resistance seem to be a high nutritional intake of pork and chicken and concomitantly prescribed calcium supplements and proton pump inhibitors. Modification of antibiotic use in animals or diminishing meat consumption as well as temporarily stopping the prescription of concomitant drugs that could affect bioavailability need further evaluation as prevention strategies for ciprofloxacin resistance.
